The purpose of the study is to determine whether taking the two medicines at the same time changes how each one is absorbed and processed in the body. Participants will receive a single dose of each medicine alone and then a single dose of both medicines together, with the order chosen at random, while fasting. Blood samples will be collected to assess the pharmacokinetic and bioavailability characteristics of the drugs, and any side effects will be recorded.

The study will evaluate the safety and tolerability of the medicines when used together and will involve only a short period of observation after the single dose administration.

The investigation compares this single capsule to three separate medications taken at the same time: Crestor, Norvasc, and Tritace. Participants in the study will undergo a process where they receive different treatments during two different periods. This cross-over approach means that each person will receive both the combination capsule and the individual tablets at different times to allow for a direct comparison of how the body processes the medicine.

During the study, the way the body absorbs and uses the substances will be monitored while participants are in a fasting state, meaning they will not eat before taking the medication. The focus is on how the medication moves through the body after it is swallowed.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

Participants in the study may receive Baxdrostat, which is taken as an oral tablet, either by itself or combined with Dapagliflozin. In some cases, the medication Forxiga is used, which contains the active substance dapagliflozin. Some individuals may also receive a placebo instead of the second medication. This is a double-blind study, meaning that neither the participants nor the researchers know which specific treatment is being administered during the course of the trial.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

The study will use Dapagliflozin film-coated tablets containing 10 milligrams of the medication, which will be taken by mouth once daily. Some participants will receive the active medication, while others will receive a placebo. The treatment period will last for 78 weeks, during which the effects of the medication on heart health and kidney function will be monitored.

The main purpose of this research is to determine if adding this medication to regular blood pressure treatment can lower the risk of serious heart-related events, such as heart attacks, strokes, and kidney problems. The study will also look at how well the medication controls blood pressure and its effects on overall health and quality of life.

The purpose of this trial is to evaluate how effective these substances are when used together to lower blood pressure in people with resistant hypertension. This is a three-way cross-over phase IIa trial, which means participants will receive different treatment combinations at different times during the study, allowing researchers to compare the effects of these combinations within the same individuals.

The study will measure changes in systolic blood pressure (the top number in a blood pressure reading) and diastolic blood pressure (the bottom number) using both office measurements and 24-hour ambulatory blood pressure monitoring (a method that measures blood pressure throughout the day and night). The trial will specifically look at patients who have high levels of certain substances in their blood that may contribute to their resistant hypertension.

Participants in the study will be randomly assigned to receive either the combination of Baxdrostat and Dapagliflozin or Dapagliflozin with a placebo. A placebo is a substance with no active medication. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, ensuring unbiased results. The treatment period will last up to 60 days, and participants will take the medication in the form of tablets.

The study aims to monitor the health of the participants over time, focusing on changes in kidney function and heart health. The researchers will look for any significant decline in kidney function, the need for dialysis or kidney transplant, and any heart-related deaths. The study will also track changes in blood pressure and other health markers. This research hopes to provide valuable insights into better treatment options for people with CKD and high blood pressure.

The purpose of the study is to find the most effective treatment approach for patients whose high blood pressure is not well controlled with their current medications. The study is divided into three phases to evaluate different treatment strategies and compare the effectiveness of various medication combinations.

During the trial, participants will receive different combinations of blood pressure medications as tablets taken by mouth. The treatment period lasts up to 30 weeks, during which doctors will monitor blood pressure using various measurement methods to determine how well the medications are working. The medications being tested include different types of drugs that work in various ways to lower blood pressure, such as water pills (diuretics), calcium channel blockers, and drugs that affect blood vessel function.

The study tests whether allopurinol, a medication that lowers uric acid levels in the blood, can help reduce the risk of cardiovascular events. Some participants will receive allopurinol tablets, while others will receive a placebo. The treatment will continue for approximately 5 years, during which participants will have regular check-ups to monitor their health status.

The main focus is to determine if allopurinol can prevent serious cardiovascular events such as heart problems, strokes, or the need for heart-related procedures. The study will also track other health changes, including heart function, blood vessel health, and the presence of long-COVID symptoms. Regular blood tests and heart examinations will be performed to monitor participants’ health throughout the study period.

The purpose of the study is to determine which treatment strategy is more effective in managing blood pressure in patients who are both obese and have hypertension. Participants in the study will receive either eplerenone or irbesartan, and their blood pressure will be monitored over a period of time to assess the effectiveness of each treatment. The study will also involve the use of a placebo to help compare the results.

Throughout the study, participants will take their assigned medication orally, and their progress will be tracked over several weeks. The study aims to provide valuable information on how these medications can help manage blood pressure in patients with specific health conditions, ultimately contributing to better treatment options for those with hypertension.

Participants in the study will receive either semaglutide or a placebo, which is an injection that does not contain any active medication. The study will last for a period of 36 weeks, during which participants will receive regular injections and follow a healthy lifestyle advice program. The trial will monitor changes in blood pressure, body weight, and other health-related factors to assess the effectiveness and safety of semaglutide in managing resistant hypertension and obesity.

The study will also evaluate the acceptability of the treatment by observing any side effects and the number of participants who continue with the treatment. Additionally, the trial will gather information on participants’ quality of life, health beliefs, and medication adherence. The goal is to determine if semaglutide can be a beneficial treatment option for people with obesity and resistant hypertension, potentially leading to better blood pressure control and overall health improvements.

Participants in the study will receive either the medication or a placebo, and their blood pressure will be monitored over a period of time. The study will last for several weeks, during which the participants’ blood pressure will be measured regularly to assess any changes. The goal is to see if nebivolol can help normalize blood pressure levels in these young patients and to monitor any side effects that may occur.

The study is designed to provide valuable information about the use of nebivolol in treating high blood pressure in adolescents, which is important because managing blood pressure early can help prevent more serious health problems later in life. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

Participants in the study will take Lorundrostat for a period of time to see if it helps maintain lower blood pressure levels. The study will also explore how starting with a dose of 25 mg once daily affects blood pressure and whether it can improve a condition called albuminuria, which involves protein in the urine and can be a sign of kidney problems. The study will include a special part where some participants will stop taking Lorundrostat to see how their blood pressure changes, which helps to understand the medication’s impact better.

The trial is designed to gather information on the long-term safety and effectiveness of Lorundrostat for people with high blood pressure that is hard to control. This information will help determine if Lorundrostat can be a reliable treatment option for managing hypertension in the future. Participants will be monitored throughout the study to ensure their safety and to collect data on how the medication affects their blood pressure and overall health.

Participants in the study will receive bosentan in the form of film-coated tablets, taken orally. The study will compare the effects of two different doses of bosentan (62.5 mg and 125 mg) over a period of eight weeks. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The main goal is to observe changes in the function of the blood vessels, particularly how they dilate or widen, which is important for controlling blood pressure.

Throughout the study, researchers will monitor changes in blood pressure, the stiffness of the arteries, and certain substances in the blood that are related to blood flow and kidney function. This research is important for finding better ways to manage high blood pressure that does not respond well to standard treatments.

Participants in the study will receive either Baxdrostat or a placebo. Baxdrostat is taken in the form of a tablet. The study will compare the effects of two different doses of Baxdrostat, 1 mg and 2 mg, over a period of 12 weeks. The main goal is to observe changes in blood pressure levels while sitting, and to monitor any side effects or safety concerns that may arise during the study.

The study will help determine if Baxdrostat is effective in lowering blood pressure in people who have not achieved their target blood pressure levels with other medications. By participating in this study, researchers hope to gather important information about the potential benefits and safety of Baxdrostat for treating high blood pressure.

Participants in the study will follow a potassium-rich diet, and the effects will be monitored over a period of six weeks. The study will compare the changes in blood potassium levels from the beginning to the end of the study. Additionally, the study will observe other health indicators such as blood pressure, kidney function, and quality of life. The study will also look at the effects on bowel movements and the occurrence of severe hyperkalemia, which is a condition where there is too much potassium in the blood.

The trial aims to ensure that the potassium-rich diet, along with the use of sodium zirconium cyclosilicate, is safe for patients with chronic kidney disease. The study will help understand if this approach can be a viable option for managing potassium levels in these patients without causing harm. The trial is expected to start recruiting participants in early 2024 and will continue until early 2025.

The purpose of the study is to determine if Baxdrostat can effectively reduce blood pressure in people with resistant hypertension. Participants will be randomly assigned to receive either Baxdrostat or the placebo. The study will last for several weeks, during which participants will take the assigned tablets and have their blood pressure monitored regularly. The main focus will be on changes in blood pressure over a 24-hour period at the end of the study.

Throughout the study, participants will continue their usual blood pressure medications alongside the trial treatment. The goal is to see if Baxdrostat can help lower blood pressure more effectively than the placebo. This research aims to provide new insights into managing resistant hypertension and improving treatment options for those affected by this condition.

The purpose of the study is to assess the effect of Lorundrostat when added to the current prescribed blood pressure medications. Participants in the study will be randomly assigned to receive either Lorundrostat or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for several weeks, during which participants will take the medication daily and attend regular check-ups to monitor their blood pressure and overall health.

Throughout the study, the dosage of Lorundrostat may be adjusted based on the participant’s response. The trial aims to determine if Lorundrostat can effectively lower blood pressure in people who have not had success with other treatments. This research is important for finding new ways to manage high blood pressure that is difficult to control with existing medications.

Participants in the study will be randomly assigned to receive either the combination of Baxdrostat and Dapagliflozin, Dapagliflozin alone, or a placebo. The study will last for up to 26 weeks, during which participants will take the medication in the form of tablets by mouth. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The main focus will be on changes in kidney function, measured by a test called estimated glomerular filtration rate (eGFR), which helps assess how well the kidneys are working.

By participating in this study, researchers hope to gather important information about the safety and effectiveness of the combination treatment for people with CKD and high blood pressure. This could potentially lead to better treatment options in the future for managing these conditions. The study is designed to ensure the safety and well-being of all participants, with regular monitoring and support provided throughout the trial period.

The purpose of the study is to evaluate how effective and safe this combination is for people who have been newly diagnosed with high blood pressure or those whose blood pressure is not well controlled with their current treatment. Participants in the study will take the medication by mouth in the form of a film-coated tablet. The study will last for a period of up to 16 weeks, during which participants will have regular check-ups to monitor their blood pressure and any potential side effects. Some participants may receive a placebo, which is a pill that looks like the medication but does not contain the active ingredients.

Throughout the study, the researchers will assess how many participants reach their target blood pressure levels and will also monitor any adverse events, which are any unwanted effects that might occur. The study aims to provide valuable information on whether this combination of irbesartan and amlodipine can be a beneficial treatment option for managing high blood pressure. Participants’ experiences and feedback will be crucial in understanding the medication’s impact on daily life and overall health.

The purpose of the study is to evaluate how effective this treatment is when used alongside regular blood pressure medications. Participants will be randomly assigned to receive either the actual treatment or a placebo procedure. The study will monitor changes in blood pressure over several months to see if the treatment helps lower it more effectively than the placebo.

Participants will continue their usual blood pressure medications throughout the study. The trial will involve several visits over a period of months, during which blood pressure will be measured and any changes in medication will be recorded. The study aims to provide more information on whether this new treatment can help people with high blood pressure manage their condition better.

Participants in the study will be given aprepitant, which is known as a substance P antagonist. This means it works by blocking a specific receptor in the body that is involved in the production of certain hormones. The study will also use a placebo, which is a substance with no active medication, to compare the effects. Another substance involved in the study is lactose monohydrate, which is used as a tablet form. The study will be conducted over a period of time, with participants taking the medication orally, meaning by mouth.

Throughout the study, various measurements will be taken to assess the effects of the treatment. These include checking the levels of aldosterone in the body, as well as monitoring blood pressure and other related factors. The study aims to provide insights into how aprepitant can help manage conditions related to obstructive sleep apnea and high blood pressure by influencing hormone levels. Participants will be monitored closely to ensure their safety and to gather accurate data on the medication’s effects.

The purpose of the study is to investigate whether colchicine can improve arterial health in patients with hypertension. Participants will be asked to take the medication orally in the form of tablets. The study will last for a period of six months, during which time the effects of the medication on the participants’ arterial stiffness will be monitored. This will be done using a method called pulse wave velocity analysis, which measures how fast blood pressure waves move through the arteries.

Throughout the study, changes in blood pressure and other health indicators will be observed. These include systolic and diastolic blood pressure, which are the two numbers used to measure blood pressure, as well as other markers of heart health. The study will help determine if colchicine can be a beneficial treatment for people with hypertension, potentially offering a new way to manage this common condition.

The purpose of the study is to assess how effective these single-pill combinations are in reducing blood pressure after 16 weeks of treatment in patients with different grades of high blood pressure. Participants will take the medication orally, and the study will monitor changes in their blood pressure throughout the day and during office visits. The study will also look at how blood pressure varies over 24 hours and how well it is controlled during office visits.

Participants in the study will be monitored over a period of 16 weeks. During this time, they will have regular check-ups to measure their blood pressure and assess the effectiveness of the treatment. The study aims to provide valuable information on how these medications can help manage high blood pressure and improve overall health outcomes for patients with this condition.

The purpose of the study is to see if using these diuretics can help reduce the risk of worsening kidney disease, heart problems, and other serious health issues in people with both high blood pressure and chronic kidney disease. Participants in the study will be randomly assigned to receive either the diuretic treatment or the usual management for their condition. The study will last for up to 36 months, during which time participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, researchers will track various health outcomes, such as the progression of kidney disease, the occurrence of heart-related events like heart attacks or strokes, and overall survival rates. The study aims to provide valuable information on whether intensifying blood pressure treatment with diuretics can offer better health outcomes for patients with these conditions. Participants will also be monitored for any side effects or safety concerns related to the medications used in the trial.